|
1.
|
Ito K, Ito H, Allen PJ, et al: Adequate
lymph node assessment for extrahepatic bile duct adenocarcinoma.
Ann Surg. 251:675–681. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Ohashi M, Kusumi T, Sato F, et al:
Expression of syndecan-1 and E-cadherin is inversely correlated
with poor patient’s prognosis and recurrent status of extrahepatic
bile duct carcinoma. Biomed Res. 30:79–86. 2009.PubMed/NCBI
|
|
3.
|
Jarnagin WR, Fong Y, DeMatteo RP, et al:
Staging, resectability, and outcome in 225 patients with hilar
cholangiocarcinoma. Ann Surg. 234:507–519. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Akoad M and Jenkins R: Proximal biliary
malignancy. Surg Clin North Am. 88:1409–1428. x–xi. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Veillette G and Castillo CF: Distal
biliary malignancy. Surg Clin North Am. 88:1429–1447. xi2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Chang K and Pastan I: Molecular cloning of
mesothelin, a differentiation antigen present on mesothelium,
mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA.
93:136–140. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Chang K, Pastan I and Willingham MC:
Isolation and characterization of a monoclonal antibody, K1,
reactive with ovarian cancers and normal mesothelium. Int J Cancer.
50:373–381. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Argani P, Iacobuzio-Donahue C, Ryu B, et
al: Mesothelin is overexpressed in the vast majority of ductal
adenocarcinomas of the pancreas: identification of a new pancreatic
cancer marker by serial analysis of gene expression (SAGE). Clin
Cancer Res. 7:3862–3868. 2001.PubMed/NCBI
|
|
9.
|
Hassan R, Kreitman RJ, Pastan I and
Willingham MC: Localization of mesothelin in epithelial ovarian
cancer. Appl Immunohistochem Mol Morphol. 13:243–247. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Ordonez NG: Value of mesothelin
immunostaining in the diagnosis of mesothelioma. Mod Pathol.
16:192–197. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Ordonez NG: Application of mesothelin
immunostaining in tumor diagnosis. Am J Surg Pathol. 27:1418–1428.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Einama T, Kamachi H, Nishihara H, et al:
Co-Expression of mesothelin and CA125 correlates with unfavorable
patient outcome in pancreatic ductal adenocarcinoma. Pancreas.
40:1276–1282. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Hassan R, Bera T and Pastan I: Mesothelin:
a new target for immunotherapy. Clin Cancer Res. 10:3937–3942.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Li M, Bharadwaj U, Zhang R, et al:
Mesothelin is a malignant factor and therapeutic vaccine target for
pancreatic cancer. Mol Cancer Ther. 7:286–296. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Cheng WF, Huang CY, Chang MC, et al: High
mesothelin correlates with chemoresistance and poor survival in
epithelial ovarian carcinoma. Br J Cancer. 100:1144–1153. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Hassan R, Laszik ZG, Lerner M, Raffeld M,
Postier R and Brackett D: Mesothelin is overexpressed in
pancreaticobiliary adenocarcinomas but not in normal pancreas and
chronic pancreatitis. Am J Clin Pathol. 124:838–845. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Swierczynski SL, Maitra A, Abraham SC, et
al: Analysis of novel tumor markers in pancreatic and biliary
carcinomas using tissue microarrays. Hum Pathol. 35:357–366. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Baba K, Ishigami S, Arigami T, et al:
Mesothelin expression correlates with prolonged patient survival in
gastric cancer. J Surg Oncol. 105:195–199. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Einama T, Homma S, Kamachi H, et al:
Luminal membrane expression of mesothelin is a prominent poor
prognostic factor for gastric cancer. Br J Cancer. 107:137–142.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Zhao H, Davydova L, Mandich D, Cartun RW
and Ligato S: S100A4 protein and mesothelin expression in dysplasia
and carcinoma of the extrahepatic bile duct. Am J Clin Pathol.
127:374–379. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Sobin LH and Wittekind CW: TNM
Classification of Malignant Tumors. 6th edition. Wiley-Liss; New
York: 2002
|
|
22.
|
Inami K, Kajino K, Abe M, et al: Secretion
of N-ERC/mesothelin and expression of C-ERC/mesothelin in human
pancreatic ductal carcinoma. Oncol Rep. 20:1375–1380.
2008.PubMed/NCBI
|
|
23.
|
Shimizu A, Hirono S, Tani M, et al:
Coexpression of MUC16 and mesothelin is related to the invasion
process in pancreatic ductal adenocarcinoma. Cancer Sci.
103:739–746. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Bharadwaj U, Marin-Muller C, Li M, Chen C
and Yao Q: Mesothelin overexpression promotes autocrine IL-6/sIL-6R
trans-signaling to stimulate pancreatic cancer cell proliferation.
Carcinogenesis. 32:1013–1024. 2011. View Article : Google Scholar
|
|
25.
|
Bharadwaj U, Marin-Muller C, Li M, Chen C
and Yao Q: Mesothelin confers pancreatic cancer cell resistance to
TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and
IL-6/Mcl-1 overexpression. Mol Cancer. 10:1062011.PubMed/NCBI
|
|
26.
|
Chang MC, Chen CA, Hsieh CY, et al:
Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K
pathway. Biochem J. 424:449–458. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Hassan R, Schweizer C, Lu KF, et al:
Inhibition of mesothelin-CA-125 interaction in patients with
mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009:
implications for cancer therapy. Lung Cancer. 68:455–459. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Bharadwaj U, Li M, Chen C and Yao Q:
Mesothelin-induced pancreatic cancer cell proliferation involves
alteration of cyclin E via activation of signal transducer and
activator of transcription protein 3. Mol Cancer Res. 6:1755–1765.
2008. View Article : Google Scholar
|
|
29.
|
Inami K, Abe M, Takeda K, et al: Antitumor
activity of anti-CERC/mesothelin monoclonal antibody in vivo.
Cancer Sci. 101:969–974. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Yen MJ, Hsu CY, Mao TL, et al: Diffuse
mesothelin expression correlates with prolonged patient survival in
ovarian serous carcinoma. Clin Cancer Res. 12:827–831. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Hudis CA: Trastuzumab - mechanism of
action and use in clinical practice. N Engl J Med. 357:39–51. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Huang TW, Wang CH and Hsieh CB: Effects of
the anti-epidermal growth factor receptor antibody cetuximab on
cholangiocarcinoma of the liver. Onkologie. 30:129–131. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Sprinzl MF, Schimanski CC, Moehler M,
Schadmand-Fischer S, Galle PR and Kanzler S: Gemcitabine in
combination with EGF-Receptor antibody (Cetuximab) as a treatment
of cholangiocarcinoma: a case report. BMC Cancer. 6:1902006.
View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Bralet MP, Bellin MF, Guettier C, Adam R
and Paule B: Response to cetuximab and gemcitabine-oxaliplatin in
an advanced case of intrahepatic cholangiocarcinoma. Clin Oncol (R
Coll Radiol). 18:4262006. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Kreitman RJ, Hassan R, Fitzgerald DJ and
Pastan I: Phase I trial of continuous infusion anti-mesothelin
recombinant immunotoxin SS1P. Clin Cancer Res. 15:5274–5279. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Hassan R, Cohen SJ, Phillips M, et al:
Phase I clinical trial of the Chimeric anti-mesothelin monoclonal
antibody MORAb-009 in patients with mesothelin expressing cancers.
Clin Cancer Res. 16:6132–6138. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Hassan R, Bullock S, Premkumar A, et al:
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin
given as a bolus I.V. infusion to patients with
mesothelin-expressing mesothelioma, ovarian, and pancreatic
cancers. Clin Cancer Res. 13:5144–5149. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Hassan R, Ebel W, Routhier EL, et al:
Preclinical evaluation of MORAb-009, a chimeric antibody targeting
tumor-associated mesothelin. Cancer Immun. 7:202007.PubMed/NCBI
|
